Amended Current Report Filing (8-k/a)
April 13 2017 - 6:05AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 12, 2017 (April 12, 2017)
Aerie Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36152
|
|
20-3109565
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
2030 Main Street, Suite 1500
Irvine, California 92614
(Address of principal executive offices) (Zip code)
Registrants telephone number, including area code: (949) 526-8700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
EXPLANATORY NOTE
Aerie Pharmaceuticals, Inc. (the Company) is furnishing this Amendment No. 1 to its Current Report on Form 8-K (Amendment
No. 1) furnished with the SEC on April 12, 2017 (the Original Form 8-K), to refurnish the slides describing the six-month topline results of Rocket 4 because Slide 9 in Exhibit 99.2 included in the Original Form 8-K
included only the Companys logo. The slides presented by management and available on the Companys website (aeriepharma.com) remain unchanged.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits.
The following exhibit shall be deemed to be furnished, and not filed:
|
|
|
99.1
|
|
Rhopressa
TM
(netarsudil ophthalmic solution) 0.02% Rocket 4 Phase 3 6-Month Topline Results.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
AERIE PHARMACEUTICALS, INC.
|
|
|
|
|
Date: April 12, 2017
|
|
|
|
By:
|
|
/s/ Richard J. Rubino
|
|
|
|
|
|
|
Richard J. Rubino
|
|
|
|
|
|
|
Chief Financial Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
|
|
Description
|
|
|
99.1
|
|
Rhopressa
TM
(netarsudil ophthalmic solution) 0.02% Rocket 4 Phase 3 6-Month Topline Results.
|
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Apr 2023 to Apr 2024